NASDAQ:TLSI TriSalus Life Sciences (TLSI) Stock Price, News & Analysis $5.00 -0.22 (-4.21%) (As of 09/6/2024 ET) Add Compare Share Share Today's Range$4.96▼$5.3150-Day Range$4.98▼$5.8952-Week Range$3.32▼$10.42Volume21,050 shsAverage Volume38,378 shsMarket Capitalization$135.80 millionP/E RatioN/ADividend YieldN/APrice Target$13.33 Stock AnalysisStock AnalysisAnalyst ForecastsChartCompetitorsEarningsFinancialsHeadlinesOwnershipSEC FilingsShort InterestTrendsStock AnalysisAnalyst ForecastsChartCompetitorsEarningsFinancialsHeadlinesOwnershipSEC FilingsShort InterestTrends Get TriSalus Life Sciences alerts: Email Address TriSalus Life Sciences MarketRank™ Stock AnalysisAnalyst RatingBuy3.00 Rating ScoreUpside/Downside166.7% Upside$13.33 Price TargetShort InterestHealthy0.79% of Float Sold ShortDividend StrengthN/ASustainabilityN/ANews SentimentN/AInsider TradingN/AProj. Earnings GrowthN/ASee Full Details Hide Full Details Overall MarketRank™New Rank-Based ScoringMarketRank™ is calculated by averaging available category scores (with extra weight given to analysis and valuation), then ranking the company's weighted average against that of other companies.2.98 out of 5 starsMedical Sector262nd out of 910 stocksSurgical & Medical Instruments Industry35th out of 95 stocks 3.5 Analyst's Opinion Consensus RatingTriSalus Life Sciences has received a consensus rating of Buy. The company's average rating score is 3.00, and is based on 3 buy ratings, no hold ratings, and no sell ratings.Amount of Analyst CoverageTriSalus Life Sciences has only been the subject of 1 research reports in the past 90 days.Read more about TriSalus Life Sciences' stock forecast and price target. Previous Next 4.0 Short Interest Percentage of Shares Shorted0.79% of the float of TriSalus Life Sciences has been sold short.Short Interest Ratio / Days to CoverTriSalus Life Sciences has a short interest ratio ("days to cover") of 1, which is generally considered an acceptable ratio of short interest to trading volume.Change versus previous monthShort interest in TriSalus Life Sciences has recently decreased by 4.20%, indicating that investor sentiment is improving. Previous Next 0.0 Dividend Strength Dividend YieldTriSalus Life Sciences does not currently pay a dividend.Dividend GrowthTriSalus Life Sciences does not have a long track record of dividend growth. Previous Next N/A Sustainability and ESG Overall ESG (Environmental, Social, and Governance) ScoreThere is no current Upright™ data available for TLSI. Previous Next 0.6 News and Social Media Coverage MarketBeat Follows2 people have added TriSalus Life Sciences to their MarketBeat watchlist in the last 30 days. Previous Next 1.7 Company Ownership Insider Buying vs. Insider SellingIn the past three months, TriSalus Life Sciences insiders have not sold or bought any company stock.Percentage Held by Insiders76.20% of the stock of TriSalus Life Sciences is held by insiders. A high percentage of insider ownership can be a sign of company health.Percentage Held by InstitutionsOnly 2.58% of the stock of TriSalus Life Sciences is held by institutions.Read more about TriSalus Life Sciences' insider trading history. Previous Next N/A Earnings and Valuation Read more about TriSalus Life Sciences' valuation and earnings. Previous Next See Top Rated MarketRank™ Stocks Here Ad Porter & CompanyThe death of Nvidia?Today, I’m warning of another looming catastrophe. Only this time, it’s not in pot stocks, cryptos, or U.S. housing… it's in artificial intelligence. And unless you know what’s really going on in this sector, you could be wiped out. You see, while there is no doubt that the recent advancements in artificial intelligence are game-changing and will drive colossal innovation in every sector of the economy... There's also no escaping that The Big AI Die-Up is coming.So go here now to read my new report The Big AI Die-Up… while you still can. About TriSalus Life Sciences Stock (NASDAQ:TLSI)TriSalus Life Sciences, Inc., a medical technology company, researches, develops, and sells drug delivery technologies and immune-oncology therapeutics for the treatment of liver and pancreatic cancer. The company offers Pressure Enabled Drug Delivery infusion systems, such as the TriNav infusion system, which is used in transarterial radioembolization and chemoembolization procedures for patients with liver cancer and metastases; and the Pancreatic Retrograde Venous Infusion device, which is in Phase 1 clinical trial, for locally advanced pancreatic cancer. It also develops nelitolimod, an investigational immunotherapeutic in Phase 1 clinical trial for the treatment of uveal melanoma with liver metastases, hepatocellular carcinoma, intrahepatic cholangiocarcinoma, and locally advanced pancreatic ductal adenocarcinoma. The company serves interventional radiologists, IR technicians, medical oncologists, nursing support, value analysis committee staff, and patients through its sales representatives and sales managers. TriSalus Life Sciences, Inc. was founded in 2009 and is headquartered in Westminster, Colorado.Read More TLSI Stock Price History View Price History Chart DataSkip Price History Chart 30 days | 90 days | 365 days | Advanced Chart TLSI Stock News HeadlinesAugust 30, 2024 | americanbankingnews.comTriSalus Life Sciences (NASDAQ:TLSI) Shares Up 5%August 21, 2024 | uk.finance.yahoo.comTriSalus Life Sciences, Inc. (TLSIW)September 7, 2024 | Deal Maker (Ad)The solution to fast food’s wage hike crisisShake Shack will be closing six California locations in response to the recent $20/hour minimum wage increase, according to the NY Post. With a sky-high 150% turnover rate, the fast food industry is already grappling with labor issues before taking into account these wage hikes. The industry will need a projected 1 million new workers every year through 2032.August 18, 2024 | investing.comTriSalus stock holds Buy rating with $11 targetAugust 16, 2024 | msn.comTriSalus Life Sciences, Inc. (NASDAQ:TLSI) Q2 2024 Earnings Call TranscriptAugust 15, 2024 | finanznachrichten.deTriSalus Reports Q2 2024 Financial Results and Business UpdateAugust 15, 2024 | msn.comTLSI Stock Earnings: TriSalus Life Sciences Beats EPS, Beats Revenue for Q2 2024August 1, 2024 | stockhouse.comTriSalus Life Sciences to Host Second Quarter 2024 Financial Results Conference CallSeptember 7, 2024 | Deal Maker (Ad)The solution to fast food’s wage hike crisisShake Shack will be closing six California locations in response to the recent $20/hour minimum wage increase, according to the NY Post. With a sky-high 150% turnover rate, the fast food industry is already grappling with labor issues before taking into account these wage hikes. The industry will need a projected 1 million new workers every year through 2032.June 26, 2024 | businesswire.comTriSalus Life Sciences Announces Expiration and Results of Exchange Offer and Consent Solicitation Relating to WarrantsJune 3, 2024 | businesswire.comTriSalus Life Sciences Highlights Clinical Data from Phase 1b PERIO-02 Trial, Studying Delivery of Nelitolimod via Pressure-Enabled Drug Delivery in Patients with Hepatocellular Carcinoma or Intrahepatic Cholangiocarcinoma at 2024 ASCO Annual MeetingMay 24, 2024 | businesswire.comTriSalus Life Sciences Announces Commencement of Exchange Offer and Consent Solicitation Relating to WarrantsMay 16, 2024 | seekingalpha.comTLSI TriSalus Life Sciences, Inc.May 16, 2024 | msn.comTriSalus Life Sciences, Inc. (NASDAQ:TLSI) Q1 2024 Earnings Call TranscriptMay 15, 2024 | investorplace.comTLSI Stock Earnings: TriSalus Life Sciences Beats EPS, Beats Revenue for Q1 2024May 15, 2024 | businesswire.comTriSalus Reports Q1 2024 Financial Results and Business UpdateMay 11, 2024 | msn.comJonesTrading Initiates Coverage of TriSalus Life Sciences (TLSI) with Buy RecommendationMay 7, 2024 | businesswire.comTriSalus Life Sciences Appoints Liselotte Hyveled to its Board of DirectorsSee More Headlines Receive TLSI Stock News and Ratings via Email Sign-up to receive the latest news and ratings for TriSalus Life Sciences and its competitors with MarketBeat's FREE daily newsletter. Email Address Company Calendar Last Earnings8/14/2024Today9/07/2024Next Earnings (Estimated)11/12/2024Fiscal Year End12/31/2024Get Stock AlertsIndustry, Sector and Symbol Stock ExchangeNASDAQ SectorMedical Industry Surgical & medical instruments Sub-IndustryMedical Equipment Current SymbolNASDAQ:TLSI Previous SymbolNASDAQ:TLSI CUSIPN/A CIK1826667 Webtrisaluslifesci.com Phone888-321-5212FaxN/AEmployees106Year FoundedN/APrice Target and Rating Average Stock Price Target$13.33 High Stock Price Target$16.00 Low Stock Price Target$12.00 Potential Upside/Downside+166.7%Consensus RatingBuy Rating Score (0-4)3.00 Research Coverage3 Analysts Profitability EPS (Most Recent Fiscal Year)N/A Trailing P/E RatioN/A Forward P/E RatioN/A P/E GrowthN/ANet Income$-59,040,000.00 Net Margins-219.71% Pretax Margin-219.67% Return on EquityN/A Return on Assets-192.99% Debt Debt-to-Equity RatioN/A Current Ratio2.33 Quick Ratio2.04 Sales & Book Value Annual Sales$24.74 million Price / Sales5.49 Cash FlowN/A Price / Cash FlowN/A Book Value($0.82) per share Price / Book-6.10Miscellaneous Outstanding Shares27,159,000Free Float6,464,000Market Cap$135.80 million OptionableNot Optionable Beta0.48 The Best High-Yield Dividend Stocks for 2024Looking to generate income with your stock portfolio? Use these ten stocks to generate a safe and reliable source of investment income.Get This Free Report Key ExecutivesMs. Mary T. Szela B.S.N. (Age 60)M.B.A., CEO, President & Director Comp: $880.67kMr. Sean Edward Murphy (Age 71)CFO & Director Comp: $628.75kDr. Steven C. Katz F.A.C.S. (Age 49)M.D., Chief Medical Officer & Chairman of Scientific Advisory Board Comp: $849.89kMs. Lori Ann SantamariaVice President of OperationsDr. Bryan F. Cox Ph.D. (Age 62)Chief Scientific & Manufacturing Officer Mr. James E. YoungSenior VP of Investor Relations & TreasurerMs. Rachel GarciaMarketing ManagerDr. Richard B. Marshak M.B.A. (Age 65)MBA, VMD, Senior Vice President of Corporate Development & Strategy Ms. Jennifer L. Stevens J.D. (Age 63)Chief Regulatory Officer Comp: $630kMs. Jodi Devlin (Age 62)President of Commercial Operations More ExecutivesKey CompetitorsZimVieNASDAQ:ZIMVJin Medical InternationalNASDAQ:ZJYLTreace Medical ConceptsNASDAQ:TMCINano-X ImagingNASDAQ:NNOXClearPoint NeuroNASDAQ:CLPTView All CompetitorsInstitutional OwnershipDuquesne Family Office LLCBought 110,966 shares on 8/15/2024Ownership: 1.572%Highbridge Capital Management LLCBought 214,545 shares on 8/12/2024Ownership: 0.790%Wolverine Asset Management LLCBought 43,480 shares on 8/2/2024Ownership: 0.160%View All Institutional Transactions TLSI Stock Analysis - Frequently Asked Questions How have TLSI shares performed this year? TriSalus Life Sciences' stock was trading at $8.45 at the beginning of 2024. Since then, TLSI shares have decreased by 40.8% and is now trading at $5.00. View the best growth stocks for 2024 here. How were TriSalus Life Sciences' earnings last quarter? TriSalus Life Sciences, Inc. (NASDAQ:TLSI) posted its quarterly earnings data on Wednesday, August, 14th. The company reported ($0.21) earnings per share for the quarter. The business had revenue of $7.36 million for the quarter. Who are TriSalus Life Sciences' major shareholders? TriSalus Life Sciences' top institutional investors include Duquesne Family Office LLC (1.57%), Highbridge Capital Management LLC (0.79%) and Wolverine Asset Management LLC (0.16%). How do I buy shares of TriSalus Life Sciences? Shares of TLSI stock can be purchased through any online brokerage account. Popular online brokerages with access to the U.S. stock market include Charles Schwab, E*TRADE, Fidelity, and Vanguard Brokerage Services. Compare Top Brokerages Here. This page (NASDAQ:TLSI) was last updated on 9/7/2024 by MarketBeat.com Staff From Our PartnersPerfect Crypto Buying Opportunity for 50 CentsWhen cryptos take a hit, the mom and pop investors run for the hills. But the top investors keep buying wit...Crypto 101 Media | SponsoredThe solution to fast food’s wage hike crisisShake Shack will be closing six California locations in response to the recent $20/hour minimum wage increase,...Deal Maker | SponsoredPre-IPO| 32,481% Growth: First Disruption to $martphones in 15 Years🤳45M Users | 32,481% Growth Rate Get in on the biggest disruption to smartphones in over a decade. Reg A inv...Mode Mobile | SponsoredTim Sykes’ Urgent Trade Alert: “Make this move now”WARNING: 80 Wall Street banks are gearing up for MASSIVE D.C. shock This $2 trillion D.C. shock is NOT abou...Timothy Sykes | SponsoredBiden’s Capital Gains Tax to Devastate Savings!Don't let the corrupt elites dictate your future—ACT NOW! This guide is your first step towards financial inde...Golden Crest | SponsoredSay Goodbye to the US DollarThe warning signs are everywhere… According to experts, the United States Dollar is "as good as doomed." ...Sasco Gold LLC | SponsoredChina Stockpiling Gold “Like No Tomorrow”For 18 consecutive months, China’s central bank has increased its gold reserve. The country, with a populat...True Gold Republic | SponsoredTrump’s weapon lurks in abandoned AmericaUnemployment is sky-high, wages are at record lows. Addiction has overwhelmed these once thriving coal towns. ...Porter & Company | Sponsored Adding Choose a watchlist: Watchlist Adding You have already added five stocks to your watchlist. Upgrade to MarketBeat All Access to add more stocks to your watchlist. Adding TriSalus Life Sciences, Inc. Please log in to your account or sign up in order to add this asset to your watchlist. Share TriSalus Life Sciences With A Colleague Link copied to clipboard. Get 30 Days of MarketBeat All Access for Free Sign up for MarketBeat All Access to gain access to MarketBeat's full suite of research tools. Start Your 30-Day Trial MarketBeat All Access Features Best-in-Class Portfolio Monitoring Get personalized stock ideas. Compare portfolio to indices. Check stock news, ratings, SEC filings, and more. Stock Ideas and Recommendations See daily stock ideas from top analysts. Receive short-term trading ideas from MarketBeat. Identify trending stocks on social media. Advanced Stock Screeners and Research Tools Use our seven stock screeners to find suitable stocks. Stay informed with MarketBeat's real-time news. Export data to Excel for personal analysis. Sign in to your free account to enjoy these benefits In-depth profiles and analysis for 20,000 public companies. Real-time analyst ratings, insider transactions, earnings data, and more. Our daily ratings and market update email newsletter. Sign in to your free account to enjoy all that MarketBeat has to offer. Sign In Create Account Your Email Address: Email Address Required Your Password: Password Required Log In or Sign in with Facebook Sign in with Google Forgot your password? Your Email Address: Please enter your email address. Please enter a valid email address Choose a Password: Please enter your password. Your password must be at least 8 characters long and contain at least 1 number, 1 letter, and 1 special character. Create My Account (Free) or Sign in with Facebook Sign in with Google By creating a free account, you agree to our terms of service. This site is protected by reCAPTCHA and the Google Privacy Policy and Terms of Service apply.
Free TLSI Stock Alerts